Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design (original) (raw)

PLGA-based Nanoparticles: A New Paradigm in Biomedical Applications

Three decades back polymers were first introduced as bioresorbable surgical devices. Since then polymer based nanoparticles have intrigued many research groups to be extensively used in a variety of fields. Nanocarrier formulated with the US FDA and EMA approved biocompatible and biodegradable polymers are being explored for the controlled delivery of various therapeutic agents. Amidst the various polymers synthesized for formulating polymeric nanoparticles PLGA has enticed considerable attention. PLGA possess many alluring properties such as controlled and sustained release properties, low cytotoxicity, long standing track records in biomedical applications, biocompatibility with tissues and cells, prolonged residence time, and targeted delivery. The prime objective of this review is to comprehensively address the issues related to PLGA based nanoparticles with special reference to methods of preparation, characterization techniques, surface modification, mechanism of drug release and the pitfalls. The review also critically addresses the developmental aspects of PLGA based nanocarriers in terms of targeted drug delivery, and exploring their efficacy in vitro and in vivo.

Recent applications of PLGA based nanostructures in drug delivery

Colloids and surfaces. B, Biointerfaces, 2017

Over the years, issues associated with non-biodegradable polymers have paved the way for biodegradable polymers in the domain of pharmaceutical and biomedical sciences. Poly (lactic-co-glycolic acid) (PLGA) is considered one of the most thrivingly synthesized biodegradable polymers. To formulate polymeric nanostructures, PLGA has attained noteworthy attention due to its controllable properties, complete biodegradability and biocompatibility, well defined formulation techniques and easy processing. This review focuses on fabrication techniques of PLGA based nanostructures and their advanced biomedical applications covering drug delivery and in-vivo imaging. Researchers have extensively investigated the potential of PLGA nanoparticles for target specific and controlled delivery of various micro and macromolecules including drugs, peptides, proteins, monoclonal antibodies, growth factors and DNA in multifarious biomedical applications like neurodegenerative and cardiovascular diseases,...

L-dopa co-drugs in nanostructured lipid carriers: A comparative study

Materials science & engineering. C, Materials for biological applications, 2017

This paper describes the production and characterization of nanostructured lipid carriers (NLC) containing four different levodopa (LD) co-drugs (PD), named PDA (3,4-diacetyloxy-LD-caffeic acid co-drug), PDB (lipoic acid-dopamine co-drug), PDC (lipoic acid-3,4-diacetoxy-dopamine co-drug), and PDD (dimeric LD co-drug containing an alkyl linker), with therapeutic potential in Parkinson's disease. These co-drugs were produced with the aim of prolonging the pharmacological activity of LD, enhancing its absorption and protecting it from metabolism. These compounds were characterized by very low water solubility that limits their systemic administration. To improve the solubility of these LDPD, NLC were considered. The obtained NLC showed acceptable particle size and a good stability up to two months from preparation. Cryo-TEM morphological characterization revealed no substantial differences between unloaded and co-drug loaded NLC. In vitro studies showed that the LDPD loaded NLC pro...